The shares of an Indian pharmaceutical company is in focus. After the company’s financial results show robust Revenue growth of 92 percent Y-O-Y, and the Net profits are up by 389 percent.
The shares of Astal Laboratories Ltd, with a market capitalization of Rs. 164.39 crores on Tuesday. Its shares are trading at a CMP of Rs 93, against the previous closing price of Rs 93.19. The stock was up by close to 5 percent intraday. The stock has given multibagger returns of 112.07 percent in the past year.
What Happened
Astal Laboratories Ltd, a company involved in the business of Pharmaceuticals and Bulk Drugs Formulations, announced its results for the Financial year ‘25. Its Revenue grew by 92 percent YoY from Rs 12.2 Crores in Q4FY24 to Rs 23.5 Crores in Q4FY25, and it has increased by close to 62 percent QoQ from Rs 14.5 Crores in Q3FY25 to Rs 23.5 Crores in Q4FY25.
Its Net Profit grew by 389 percent YoY from Rs. 0.56 Crores in Q4FY24 to Rs. 2.74 Crores in Q4FY25. The Net profits have grown by 10 percent QoQ from Rs. 2.49 Crores in Q3FY25 to Rs. 2.74 Crores in Q4FY25.
The company’s Earnings Before Interest, Depreciation, and Taxes (EBIDT) has also grown by 621 percent YOY from Rs 0.58 crores in Q4FY24 to Rs 4.18 crores in Q4FY25. Its EPS has also grown by 172 percent YOY from Rs. 0.57 in Q4FY24 to Rs. 1.55 in Q4FY25.
About the company
Astal Laboratories is a premier Pharmaceutical Active Pharmaceutical Ingredient (API) developer, committed to transforming scientific discoveries into life-changing therapies. With a team of world-class scientists, researchers, and industry experts, we strive to address the most pressing health challenges and deliver effective solutions that enhance patient care and outcomes. Astal Laboratories specializes in producing high-value fine chemicals. Besides regular products, Astal Laboratories develops new products based on customers’ requirements.
Written by Likesh Babu S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies
